<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01619683</url>
  </required_header>
  <id_info>
    <org_study_id>ZA-303</org_study_id>
    <nct_id>NCT01619683</nct_id>
  </id_info>
  <brief_title>Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism</brief_title>
  <official_title>A 12 Month, Single Blind, Placebo Controlled, Phase III Study to Assess the Effects of Enclomiphene Citrate Treatment On Bone Mineral Density in Men With Secondary Hypogonadism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repros Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repros Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effects of 12 months of treatment with Androxal on bone mineral density in&#xD;
      men with secondary hypogonadism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase III single-blind placebo-controlled safety study with a 52 week active&#xD;
      dosing period with Androxal. Safety will be assessed by physical and visual acuity exams,&#xD;
      slit lamp and fundoscopy eye exams, clinical laboratory tests, DEXA scanning, lean soft&#xD;
      tissue assessment (LST), and adverse event reporting. Results will be compared to an&#xD;
      age-matched placebo group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Mineral Density</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change in bome mineral density at the end of study compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Testosterone</measure>
    <time_frame>52 weeks</time_frame>
    <description>Changes of values from baseline in total morning Testosterone levels at week 52.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Effect of Treatment on Bone Mineral Density</condition>
  <arm_group>
    <arm_group_label>Androxal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enclomiphene citrate</intervention_name>
    <description>12.5 mg, 1 capsule, daily, oral. After 6 weeks of treatment, subjects will remain on 12.5 mg/day if their morning testosterone level is greater than 300 ng/dL. If a subject's testosterone is less than 300 ng/dL, the subject's dose will be increased to 25 mg/day</description>
    <arm_group_label>Androxal</arm_group_label>
    <other_name>Androxal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 placebo capsule per day, oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Overweight (BMI 25 to 42 kg/m2 inclusive, or BMI 23 to 42 inclusive in Asian subjects)&#xD;
             males age 18 to 60 inclusive&#xD;
&#xD;
          2. Men currently using topical testosterone products should wash-out for at least 7 days&#xD;
             before Visit 1&#xD;
&#xD;
          3. All clinical laboratory tests within normal ranges (any clinically significant&#xD;
             deviation of laboratory results will require approval of sponsor)&#xD;
&#xD;
          4. Previously or concurrently diagnosed as having secondary hypogonadism and confirmed&#xD;
             with morning testosterone &lt;300ng/dL measured twice on separate days. One of the two TT&#xD;
             levels must be confirmed at baseline. Subjects who fail this criterion will be&#xD;
             enrolled in the placebo group.&#xD;
&#xD;
          5. LH &lt;9.4 mIU/mL (at Visit 1 only)&#xD;
&#xD;
          6. Ability to complete the study in compliance with the protocol&#xD;
&#xD;
          7. Ability to understand and provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of an injectable or pelleted testosterone within 6 months prior to study (men&#xD;
             currently on topical products may be enrolled in the study after a 7-day washout&#xD;
             period)&#xD;
&#xD;
          2. Use of testosterone injection, spironolactone, cimetidine, Clomid, 5Î±-reductase&#xD;
             inhibitors, hCG, androgen, estrogen, anabolic steroid, DHEA, or herbal hormone&#xD;
             products during the study&#xD;
&#xD;
          3. Use of Clomid in the past year&#xD;
&#xD;
          4. Uncontrolled hypertension or diabetes mellitus based on the Investigator's assessment&#xD;
             at baseline. Subjects treated for Type II diabetes will be allowed into the study.&#xD;
             Newly diagnosed diabetics need to be treated for at least 48 hours before being&#xD;
             enrolled in the study&#xD;
&#xD;
          5. Clinically significant abnormal findings at screening (Visit 1), based on the&#xD;
             Investigator's assessment.&#xD;
&#xD;
          6. A hematocrit &gt;54% or a hemoglobin &gt;17 g/dL&#xD;
&#xD;
          7. Clinically significant abnormal laboratory findings at baseline (Visit 2), based on&#xD;
             the Investigator's assessment&#xD;
&#xD;
          8. Use of an investigational drug or product, or participation in a drug or medical&#xD;
             device research study within 30 days prior to receiving study medication.&#xD;
&#xD;
          9. Known hypersensitivity to Clomid&#xD;
&#xD;
         10. Symptomatic cataracts (nuclear sclerosis cataract or cortical cataract grade &gt; 2 based&#xD;
             on 0-4 scale or any trace of posterior subcapsular cataract)&#xD;
&#xD;
         11. Abnormal fundoscopy exam such as central retinal vein occlusion&#xD;
&#xD;
         12. Any condition which in the opinion of the investigator would interfere with the&#xD;
             participant's ability to provide informed consent, comply with study instructions,&#xD;
             possibly confound interpretation of study results, or endanger the participant if he&#xD;
             took part in the study&#xD;
&#xD;
         13. Irreversibly infertile or compromised fertility (cryptorchism, Kallman Syndrome,&#xD;
             primary hypogonadism, or tumors of the pituitary)&#xD;
&#xD;
         14. Current or history of breast cancer&#xD;
&#xD;
         15. Subjects with a Z-score of &lt;2&#xD;
&#xD;
         16. Hyperparathyroidism, metabolic bone disease, previous fracture of the spine, recent&#xD;
             chemotherapy, use of medications that may influence BMD (thyroid replacement therapy,&#xD;
             immunosuppressive therapy, prednisone or antiepileptic drugs&#xD;
&#xD;
         17. No intravenous or oral contrast agents within 7 days.&#xD;
&#xD;
         18. Subject weighs &gt;300 pounds (&gt;136 kg)&#xD;
&#xD;
         19. Current or history of prostate cancer or a suspicion of prostate disease unless ruled&#xD;
             out by prostate biopsy, or a PSA&gt;3.6&#xD;
&#xD;
         20. Presence or history of known hyperprolactinemia with or without a tumor&#xD;
&#xD;
         21. Chronic use of medications use such as glucocorticoids&#xD;
&#xD;
         22. History of drug abuse or chronic narcotic use including methadone&#xD;
&#xD;
         23. Subjects with known history of HIV and/or Hepatitis C&#xD;
&#xD;
         24. Subjects with end stage renal disease&#xD;
&#xD;
         25. Subjects with cystic fibrosis (mutation of the CFTR gene)&#xD;
&#xD;
         26. Enrollment in a previous Androxal study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rancho Cucamonga</city>
        <state>California</state>
        <zip>91730</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami Gardens</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08690</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.reprosrx.com</url>
    <description>Sponsor's corporate web page</description>
  </link>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>June 12, 2012</study_first_submitted>
  <study_first_submitted_qc>June 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2012</study_first_posted>
  <last_update_submitted>September 29, 2014</last_update_submitted>
  <last_update_submitted_qc>September 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

